Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Oct;34(4):337–343. doi: 10.1111/j.1365-2125.1992.tb05640.x

Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

N M Wheeldon 1, D G McDevitt 1, B J Lipworth 1
PMCID: PMC1381417  PMID: 1333781

Abstract

1. The aims of this study were to assess the relative beta 1/beta 2 selectivity of the antagonist and partial agonist activity (PAA) of celiprolol in man. 2. Eight normal males received single oral doses of celiprolol 200 mg (C200), 400 mg (C400) and 800 mg (C800); atenolol 50 mg (A50), 100 mg (A100) and 200 mg (A200); nadolol 40 mg (N40) and placebo (PL), administered in a single-blind, randomised crossover design. 3. At rest, in the presence of low levels of circulating adrenaline and noradrenergic tone, a low dose of celiprolol (C200) showed evidence of beta 1-PAA by significant increases in systolic blood pressure and resting heart rate. At higher doses (C400, C800), beta 2-PAA became evident by a significant increase in postural finger tremor, whereas C200 had no effect. 4. In the presence of a beta 1-adrenoceptor agonist, as assessed by reduction of exercise tachycardia, increasing doses of celiprolol produced significantly less beta 1-adrenoceptor blockade compared with atenolol. Furthermore, there was no increase in beta 1-adrenoceptor blockade beyond C400. 5. In the presence of a beta 2-adrenoceptor agonist, as assessed by blunting of terbutaline-induced chronotropic, hypokalaemic and finger tremor responses, celiprolol exhibited less beta 2-adrenoceptor blockade than comparable doses of atenolol used in clinical practice. 6. Exercise hyperkalaemia was blunted significantly by C400 and C800 in comparison with all doses of atenolol and nadolol.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
337

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold J. M., McDevitt D. G. Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists. Clin Pharmacol Ther. 1986 Aug;40(2):199–208. doi: 10.1038/clpt.1986.164. [DOI] [PubMed] [Google Scholar]
  2. Arnold J. M., O'Connor P. C., Riddell J. G., Harron D. W., Shanks R. G., McDevitt D. G. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol. 1985 May;19(5):619–630. doi: 10.1111/j.1365-2125.1985.tb02689.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berkin K. E., Walker G., Inglis G. C., Ball S. G., Thomson N. C. Circulating adrenaline and noradrenaline concentrations during exercise in patients with exercise induced asthma and normal subjects. Thorax. 1988 Apr;43(4):295–299. doi: 10.1136/thx.43.4.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonde J., Svendsen T. L., Lyngborg K., Mehlsen J., Trap-Jensen J. Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease. Br J Clin Pharmacol. 1987 Jan;23(1):35–40. doi: 10.1111/j.1365-2125.1987.tb03006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brodde O. E., Daul A., Stuka N., O'Hara N., Borchard U. Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity". Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):417–422. doi: 10.1007/BF00692910. [DOI] [PubMed] [Google Scholar]
  6. Brodde O. E., Schemuth R., Brinkmann M., Wang X. L., Daul A., Borchard U. Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jun;333(2):130–138. doi: 10.1007/BF00506515. [DOI] [PubMed] [Google Scholar]
  7. Brown H. C., Carruthers S. G., Johnston G. D., Kelly J. G., McAinsh J., McDevitt D. G., Shanks R. G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976 Nov;20(5):524–534. doi: 10.1002/cpt1976205524. [DOI] [PubMed] [Google Scholar]
  8. Brown R. A., Beck J. S. Statistics on microcomputers. A non-algebraic guide to their appropriate use in biomedical research and pathology practice. 3. Analysis of variance and distribution-free methods. J Clin Pathol. 1988 Dec;41(12):1256–1262. doi: 10.1136/jcp.41.12.1256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carruthers S. G., Twum-Barima Y. Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther. 1981 Nov;30(5):581–586. doi: 10.1038/clpt.1981.207. [DOI] [PubMed] [Google Scholar]
  10. Corea L., Bentivoglio M., Verdecchia P., Motolese M., Sorbini C. A., Grassi V., Tantucci C. Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation. Clin Pharmacol Ther. 1984 Jun;35(6):776–781. doi: 10.1038/clpt.1984.111. [DOI] [PubMed] [Google Scholar]
  11. Dimsdale J. E., Moss J. Plasma catecholamines in stress and exercise. JAMA. 1980 Jan 25;243(4):340–342. [PubMed] [Google Scholar]
  12. Doshan H. D., Brown R., Applin W. J., Kapoor M., Caruso F. S. Effects of high doses of celiprolol in asthmatic patients. J Cardiovasc Pharmacol. 1986;8 (Suppl 4):S109–S111. doi: 10.1097/00005344-198608004-00024. [DOI] [PubMed] [Google Scholar]
  13. Doshan H. D., Rosenthal R. R., Brown R., Slutsky A., Applin W. J., Caruso F. S. Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. J Cardiovasc Pharmacol. 1986;8 (Suppl 4):S105–S108. [PubMed] [Google Scholar]
  14. Dreyfuss J., Brannick L. J., Vukovich R. A., Shaw J. M., Willard D. A. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977 May-Jun;17(5-6):300–307. doi: 10.1002/j.1552-4604.1977.tb04609.x. [DOI] [PubMed] [Google Scholar]
  15. Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978 May 17;13(2):81–89. doi: 10.1007/BF00609750. [DOI] [PubMed] [Google Scholar]
  16. Frohlich E. D. Vasodilatory beta-blockers: systemic and regional hemodynamic effects. Am Heart J. 1991 Mar;121(3 Pt 2):1012–1017. doi: 10.1016/0002-8703(91)90613-m. [DOI] [PubMed] [Google Scholar]
  17. Hall J. A., Petch M. C., Brown M. J. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart. Circ Res. 1989 Sep;65(3):546–553. doi: 10.1161/01.res.65.3.546. [DOI] [PubMed] [Google Scholar]
  18. Heitz A., Schwartz J., Velly J. Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol. 1983 Dec;80(4):711–717. doi: 10.1111/j.1476-5381.1983.tb10062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Heublein B., Modersohn D., Franz N., Panzner B. Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol. Eur Heart J. 1991 May;12(5):617–623. doi: 10.1093/oxfordjournals.eurheartj.a059949. [DOI] [PubMed] [Google Scholar]
  20. Lamon K. D. Clinical safety and efficacy of celiprolol. Am Heart J. 1991 Feb;121(2 Pt 2):683–687. doi: 10.1016/0002-8703(91)90446-o. [DOI] [PubMed] [Google Scholar]
  21. Lipworth B. J., Brown R. A., McDevitt D. G. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1989 Jul;28(1):95–102. doi: 10.1111/j.1365-2125.1989.tb03510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lipworth B. J., Irvine N. A., McDevitt D. G. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135–139. doi: 10.1007/BF00280067. [DOI] [PubMed] [Google Scholar]
  23. Lipworth B. J., Irvine N. A., McDevitt D. G. The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur J Clin Pharmacol. 1991;40(5):467–471. doi: 10.1007/BF00315224. [DOI] [PubMed] [Google Scholar]
  24. Lipworth B. J., Irvine N. A., McDevitt D. G. The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Br J Clin Pharmacol. 1991 Feb;31(2):154–159. doi: 10.1111/j.1365-2125.1991.tb05504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  26. Lipworth B. J., McFarlane L. C., Coutie W. J., McDevitt D. G. Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade. Eur J Clin Pharmacol. 1989;37(3):297–300. doi: 10.1007/BF00679788. [DOI] [PubMed] [Google Scholar]
  27. Lipworth B. J., Struthers A. D., McDevitt D. G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989 Sep;140(3):586–592. doi: 10.1164/ajrccm/140.3.586. [DOI] [PubMed] [Google Scholar]
  28. Matthys H., Doshan H. D., Rühle K. H., Braig H., Pohl M., Applin W. J., Caruso F. S., Neiss E. S. The bronchosparing effect of celiprolol, a new beta 1- alpha 2-receptor antagonist on pulmonary function of propranolol-sensitive asthmatics. J Clin Pharmacol. 1985 Jul-Aug;25(5):354–359. doi: 10.1002/j.1552-4604.1985.tb02854.x. [DOI] [PubMed] [Google Scholar]
  29. McDevitt D. G., Brown H. C., Carruthers S. G., Shanks R. G. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther. 1977 May;21(5):556–566. doi: 10.1002/cpt1977215556. [DOI] [PubMed] [Google Scholar]
  30. McDevitt D. G. The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol. 1977 Aug;4(4):413–425. doi: 10.1111/j.1365-2125.1977.tb00756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. McLenachan J. M., Grant S., Ford I., Henderson E., Dargie H. J. Submaximal, but not maximal, exercise testing detects differences in the effects of beta-blockers during treadmill exercise: a study of celiprolol and atenolol. II. Am Heart J. 1991 Feb;121(2 Pt 2):691–696. doi: 10.1016/0002-8703(91)90448-q. [DOI] [PubMed] [Google Scholar]
  32. Perrone M. H., Barrett J. A. Preclinical pharmacology of celiprolol: a cardioselective beta-adrenergic antagonist and mild vasodilator. Am Heart J. 1991 Feb;121(2 Pt 2):677–683. doi: 10.1016/0002-8703(91)90445-n. [DOI] [PubMed] [Google Scholar]
  33. Pringle T. H., Riddell J. G., Shanks R. G. Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol. 1988;35(5):507–514. doi: 10.1007/BF00558246. [DOI] [PubMed] [Google Scholar]
  34. Reithmann C., Wieland F., Jakobs K. H., Werdan K. Intrinsic sympathomimetic activity of beta-adrenoceptor antagonists: down-regulation of cardiac beta 1- and beta 2-adrenoceptors. Eur J Pharmacol. 1989 Nov 7;170(3):243–255. doi: 10.1016/0014-2999(89)90545-1. [DOI] [PubMed] [Google Scholar]
  35. Strauss M. H., Reeves R. A., Smith D. L., Leenen F. H. The role of cardiac beta-1 receptors in the hemodynamic response to a beta-2 agonist. Clin Pharmacol Ther. 1986 Jul;40(1):108–115. doi: 10.1038/clpt.1986.146. [DOI] [PubMed] [Google Scholar]
  36. Struthers A. D., Quigley C., Brown M. J. Rapid changes in plasma potassium during a game of squash. Clin Sci (Lond) 1988 Apr;74(4):397–401. doi: 10.1042/cs0740397. [DOI] [PubMed] [Google Scholar]
  37. Svendsen T. L., Hartling O., Trap-Jensen J. Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol. 1979 May 21;15(4):223–228. doi: 10.1007/BF00618509. [DOI] [PubMed] [Google Scholar]
  38. Waller D. G. Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy? Br J Clin Pharmacol. 1990 Aug;30(2):157–171. doi: 10.1111/j.1365-2125.1990.tb03760.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Warnock P., Docherty J. R. Further investigation of the sites of vascular alpha 1 and alpha 2 adrenoceptors in the anaesthetised spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):67–70. doi: 10.1097/00005344-198601000-00011. [DOI] [PubMed] [Google Scholar]
  40. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411–416. doi: 10.1111/j.1365-2125.1992.tb04060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Williams M. E., Gervino E. V., Rosa R. M., Landsberg L., Young J. B., Silva P., Epstein F. H. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985 Mar 28;312(13):823–827. doi: 10.1056/NEJM198503283121304. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES